OXFORD VACMEDIX
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang - Recombinant Overlapping Peptides (ROP). These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy.
OXFORD VACMEDIX
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2012-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.oxfordvacmedix.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
12.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Ennar Pharma
Development of medicines for the treatment of psoriasis.
Current Employees Featured
Founder
Investors List
Cancer Rop
Cancer Rop investment in Series A - Oxford Vacmedix
Oxford University Innovation
Oxford University Innovation investment in Seed Round - Oxford Vacmedix
Official Site Inspections
http://www.oxfordvacmedix.com
- Host name: 92.205.145.103
- IP address: 92.205.145.103
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Oxford Vacmedix"
Home - Oxford Vacmedix
Www.oxfordvacmedix.com; [email protected] +44 (0) 1865 784074; Oxford Vacmedix UK Limited, The Magdalen Centre, The Oxford Science Park, Oxford, OX4 4GA; …See details»
About us - Oxford Vacmedix
Www.oxfordvacmedix.com; [email protected] +44 (0) 1865 784074; Oxford Vacmedix UK Limited, The Magdalen Centre, The Oxford Science Park, Oxford OX4 4GA; …See details»
Contact - Oxford Vacmedix
Www.oxfordvacmedix.com; [email protected] +44 (0) 1865 784074; Oxford Vacmedix UK Limited, The Magdalen Centre, The Oxford Science Park, Oxford, OX4 4GA; …See details»
Oxford Vacmedix - Crunchbase Company Profile & Funding
Contact Email [email protected] Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of …See details»
Oxford Vacmedix - Org Chart, Teams, Culture & Jobs
View Oxford Vacmedix's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
CEO Spotlight: Tony Coombs, Executive Chairman, …
12th October 2023. For the latest in our CEO Spotlight series, we caught up with Dr Tony Coombs, Executive Chairman of Oxford VacMedix - a spinout company making waves in the world of cancer vaccines with its impressive pre-clinical …See details»
Cancer vaccine firm Oxford Vacmedix closes $12.5m Series A funding
6th March 2018. South Korean and Chinese investors join round into Oxford University spinout developing cancer vaccines. Oxford Vacmedix UK Limited (OVM), a UK-based biopharma …See details»
Oxford Vacmedix announces completion of Phase 1a in clinical …
Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has …See details»
Oxford Vacmedix announces collaboration to develop vaccine and ...
Contact Us. Oxford University Innovation Buxton Court 3 West Way Oxford OX2 0JB. T: +44 (0) 1865 280830 . E: [email protected]See details»
Oxford Vacmedix - Craft
Oxford Vacmedix is a biotech company developing therapeutic agents for the treatment of cancer based on the recombinant overlapping peptides. These agents help to deliver immunotherapy …See details»
Oxford Vacmedix announces completion of Phase 1a in clinical …
Mar 29, 2023 The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP …See details»
MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200
Aug 10, 2021 Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping …See details»
Oxford Vacmedix CEO and Key Executive Team | Craft.co
Oxford Vacmedix's Chief Executive Officer is William Finch. Other executives include Anthony Coombs, Executive chairman; Louisa Dawson, Company Secretary and Finance Manager. …See details»
Oxford Vacmedix (UK) Funding: $12.5M - medicalstartups.org
Oxford Vacmedix develops therapeutic agents for the treatment of cancer based on the Recombinant Overlapping Peptides...See details»
Oxford Vacmedix Ltd.: harnessing the power of immunotherapy to …
Organization (CMO) in Europe. Additionally, using ROPs as diagnostic reagents, ... www.oxfordvacmedix.com Figure 1: Antigen presentation of ROP. MHC, major …See details»
Oxford Vacmedix announces lead investment for Series B fund
Nov 6, 2024 For more information: https://www.oxfordvacmedix.com. About Dx&Vx. Dx&Vx develops and researches novel biotechnology solutions for healthcare. The company offers …See details»
Oxford Vacmedix Ltd.: harnessing the power of immunotherapy to …
A new platform built around recombinant overlapping peptides (ROPs) promises quicker and cheaper production of more effective therapeutic vaccines and diagnostics for cancer and viral …See details»
UK charity Prostate Cancer Research invests in Oxford Vacmedix …
Nov 27, 2024 For more information: https://www.oxfordvacmedix.com. About Proven Connect. Bridging the gap between innovators, investors, healthcare, and patients. Proven Connect is …See details»
Cancer vaccine firm Oxford Vacmedix announces collaboration …
Cancer vaccine firm Oxford Vacmedix announces collaboration and Innovate UK grant Oxford, UK – 2nd July 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company …See details»